IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042
— ICVB-1042 is an oncolytic adenovirus for the treatment of advanced solid tumors —— Initial safety data expected in 2H 2023, followed by proof-of-concept data in 2024 — SAN DIEGO, CA., July 11, 2023 – IconOVir Bio, Inc. (IconOVir), a clinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the […]